STOCKHOLM, May 17, 2010 /PRNewswire/ -- Axelar AB, a Karolinska Development portfolio company, today announces that a submitted abstract has been accepted to the ASCO meeting in Chicago, June 2010.
The abstract containing preliminary clinical data will be publicly released on ASCO's website, http://www.asco.org on Thursday, May 20, 2010 at 6:00 PM (EDT).
"We are pleased that the abstract containing a preliminary update of the favorable clinical data has been accepted by 2010 Annual Meeting of the American Society of Clinical Oncology", says Johan Harmenberg, CEO Axelar AB.
Axelar is a Swedish biotech company founded in 2003. The company is developing an insulin-like growth factor-1 (IGF-1) receptor inhibitor for cancer treatment. Axelar is part of the Karolinska Development portfolio. http://www.axelar.se
Axelar's lead compound, AXL1717, provides a novel treatment for a wide
range of cancers. AXL1717 is the first targeted oral small-molecule IGF-1
receptor inhibitor with no effect on the insulin receptor. AXL1717 is
presently undergoing Phase I/II clinical trials and the compound combines a
|SOURCE Karolinska Development AB|
Copyright©2010 PR Newswire.
All rights reserved